Fingerprint
Dive into the research topics of 'A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically